

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

21-462

Chemistry Review(s)



NDA 21-462

ALIMTA™ (pemetrexed disodium) for Injection

Eli Lilly and Company

CMC Review 2

**Chengyi Liang, Ph.D.
Division of Oncological Drug Products**

HFD-150/810




Table of Contents

Table of Contents.....	2
Chemistry Review Data Sheet.....	3
The Chemistry Review for NDA 21-462	6
The Executive Summary.....	6
I. Recommendations	6
A. Recommendation and Conclusion on Approvability.....	6
B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable.....	6
II. Summary of Chemistry Assessments.....	6
A. Description of the Drug Product(s) and Drug Substance(s).....	7
B. Description of How the Drug Product is Intended to be Used.....	7
C. Basis for Approvability, or Not-Approval Recommendation.....	7
III. Administrative.....	7
A. Reviewer's Signature.....	7
B. Endorsement Block.....	7
C. CC Block.....	7
 Chemistry Assessment.....	 8



Chemistry Review Data Sheet

- 1. NDA #: 21-462
- 2. CHEM. REVIEW #: 2
- 3. REVIEW DATE: Dec.31, 2003
- 4. REVIEWER: Chengyi Liang, Ph.D.

5. PREVIOUS DOCUMENTS

Previous Documents

Document Date

IND 40,061

6. SUBMISSION(S) BEING REVIEWED:

Submission(s) Reviewed

Documnent Date

Original (DS)	12-31-2002
Original (DP)	09-30-2003
Amendment	09-30-2003
Amendment	11-06-2003
Amendment	12-11-2003
Amendment	12-16-2003
Amendment	12-29-2003

7. NAME & ADDRESS OF APPLICANT:

Name: Eli Lilly and Company
 Address: Lilly Corporate Center
 Indianapolis, IN 46285

Representative:

Telephone:

8. DRUG PRODUCT NAME/CODE/TYPE:


- a. Proprietary: Alimta
- b. Nonproprietary Name/USAN: Pemetrexed disodium
- c. Code Name/#: LY231514.2Na.7H₂O
- d. Chem. Type/Submission Priority
 - Chem. Type 1
 - Submission Priority P

9. LEGAL BASIS FOR SUBMISSION:

Fulfilled PDUFA filing requirements




CHEMISTRY REVIEW



NDA 21-462 Review #2, ALIMTA™ (pemetrexed disodium) for Injection, Page 4 of 13

10. PHARMACOL. CATEGORY/INDICATION: Malignant pleural mesothelioma
11. DOSAGE FORM: for injection (lyophilized powder)
12. STRENGTHS/POTENCY: 500 mg/vial
13. ROUTE OF ADMINISTRATION: IV
14. Rx/OTC DISPENSED: Rx OTC
15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM) No

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:



L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt

C₂₀H₁₉N₅O₆Na₂·7H₂O, MW = 597.49

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

DMF #	TYPE	HOLDER	ITEM REFERENCED	CODE ¹	STATUS ²	DATE REVIEW COMPLETED	COMMENTS
-	III	/	/	1	adequate	11-20-2003	None
-	III	/	/	1	adequate	9-2-2003	None
-	V	/	/			9-24-	None

Chengyi Liang, Ph.D.
Dec., 2003



CHEMISTRY REVIEW



NDA 21-462 Review #2, ALIMTA™ (pemetrexed disodium) for Injection, Page 5 of 13

			1	adequate	2001	
--	--	--	---	----------	------	--

¹ Action codes for DMF Table:

1 - DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

2 - Type 1 DMF

3 - Reviewed previously and no revision since last review

4 - Sufficient information in application

5 - Authority to reference not granted

6 - DMF not available

7 - Other (explain under "Comments")

B. Other Documents:

Document	Application Number	Description
IND	40,061	LY231514

18. STATUS:

Consults/CMC Related Reviews	Recommendation	Date	Reviewer
EES	Acceptable	12-10-2003	OC
OPDRA	Acceptable	7-11-2003	Charlie Hoppes
Methods Validation	Pending		
EA	Categorical exclusion is acceptable	11-20-2003	Chengyi Liang
Microbiology	Acceptable	10-29-2003	Paul Stinavage

APPEARS THIS WAY
ON ORIGINAL

The Chemistry Review for NDA 21-462

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

This NDA is recommended to be approved based on the submitted CMC information. The deficiencies related to the drug substance and drug product have been forwarded to the applicant during the fast-track, priority review cycle.

B. Recommendation on Phase 4 (post marketing) Commitments, Agreements and/or Risk Management Steps, if Approvable

There are no phase 4 commitments.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

ALIMTA[®], Pemetrexed for Injection, is a novel antifolate antineoplastic agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication. The drug substance, containing one chiral center, is and its structure is well characterized by ALIMTA drug product is supplied as a sterile lyophilized powder for intravenous infusion available in single-dose vials. Each 50 ml vial of ALIMTA contains pemetrexed disodium equivalent to 500 mg pemetrexed free acid and 500 mg of mannitol. Sodium hydroxide and, if necessary, hydrochloric acid are added to adjust pH. DP will be manufactured by Eli Lilly's French facility.

The drug substance, drug product, and the reconstituted drug product solution have good stability characteristics under various test conditions. The proposed 24 months shelf life of drug product is acceptable based on primary and supportive stability data.


B. Description of How the Drug Product is Intended to be Used

The applicant proposes to use this drug product to treat the patients with

Alimta for Injection is a single-use, sterile, lyophilized powder packaged in a glass vial, containing _____ of pemetrexed disodium equivalent to _____ mg of pemetrexed free acid including _____ overages as label claimed. Each 50 ml vial is reconstituted with 20 ml of commercially available 0.9% Sodium Chloride Injection without preservatives. The concentration of reconstituted drug product solution is 25 mg/ml of pemetrexed. The reconstituted pemetrexed solution must be further diluted to 100 mL with 0.9% Sodium Chloride Injection prior to intravenous infusion. The final



CHEMISTRY REVIEW



NDA 21-462 Review #2, ALIMTA™ (pemetrexed disodium) for Injection, Page 7 of 13

concentration of drug product solution to be administered is 0.25 mg/ml.

C. Basis for Approvability Recommendation

The information provided is adequate to support the approval of this NDA from a CMC perspective.

III. Administrative

A. Reviewer's Signature

/S/

Chengyi Liang, Ph.D.,
Review Chemist

/S/

Richard Lostritto, Ph.D.
Chemistry Team Leader

B. Endorsement Block

Chemist Name/Date: Chengyi Liang, Ph.D.

Chemistry Team Leader Name/Date: Richard Lostritto, Ph.D.

Project Manager Name/Date: Patricia Garvey

C. CC Block

CC:

Orig. NDA 21-462
HFD-150 Division File
HFD-150/CLiang
HFD-150/RLostritto
HFD-150/PGarvey

Chemistry Assessment

The deficiencies related to the Alimta drug substance and drug product have been addressed satisfactorily by the applicant and the commitments are also provided to solve the remaining issues.

Chengyi Liang, Ph.D.
Dec., 2003

Redacted 6

pages of trade

secret and/or

confidential

commercial

information

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Chengyi Liang
1/16/04 10:17:14 AM
CHEMIST

Richard Lostritto
1/19/04 12:31:03 PM
CHEMIST



NDA 21-462

ALIMTA™ (pemetrexed disodium) for Injection

Eli Lilly and Company

**Chengyi Liang, Ph.D.
Division of Oncological Drug Products**

HFD-150/810




Table of Contents

Table of Contents.....2

Chemistry Review Data Sheet.....5

The Chemistry Review for NDA 21-4628

The Executive Summary.....8

I. Recommendations 8

 A. Recommendation and Conclusion on Approvability.....8

 B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable..... 8

II. Summary of Chemistry Assessments..... 8

 A. Description of the Drug Product(s) and Drug Substance(s).....8

 B. Description of How the Drug Product is Intended to be Used.....8

 C. Basis for Approvability or Not-Approval Recommendation.....9

III. Administrative..... 9

 A. Reviewer's Signature.....9

 B. Endorsement Block..... 9

 C. CC Block..... 9

Chemistry Assessment.....10

 Introduction.....10

A. DRUG SUBSTANCE10

 1. DESCRIPTION AND CHARACTERIZATION.....10

 A. Description.....10

 B. Characterization/Proof of Structure.....11

 C. Physical Characterization.....17

 2. MANUFACTURE.....18

 3. SYNTHESIS/METHOD OF MANUFACTURE.....18


 A. Starting Materials - Specs & Tests.....18

 B. Reagents, Solvents and Auxiliary Materials.....21


 C. Flow Chart of Synthesis.....24

 D. Detailed Description of the Synthesis of — Drug Substance.....24

 4. IN-PROCESS CONTROL.....30



CHEMISTRY REVIEW



NDA 21-462 Review #1, ALIMTA™ (pemetrexed disodium) for Injection, Page 3 of 92

5. REPROCESSING	32
6. REFERENCE STANDARD.....	33
7. REGULATORY SPECIFICATIONS/ANALYTICAL METHODS.....	34
8. CONTAINER/CLOSURE SYSTEM FOR DRUG SUBSTANCE.....	45
9. DRUG SUBSTANCE STABILITY.....	46
A. Stability Protocol.....	46
B. Primary Stability Data.....	47
C. Supportive Stability Data.....	50
D. Highly Stressed Stability Tests.....	52
E. Retest Period.....	54
B. DRUG PRODUCT.....	55
1&2 COMPONENTS AND COMPOSITION.....	56
3. SPECIFICATIONS & METHODS FOR DRUG PRODUCT INGREDIENTS.....	57
4. MANUFACTURER.....	58
5. METHODS OF MANUFACTURING AND PACKAGING.....	59
Production Operations.....	58
6. DRUG PRODUCT PROCESS CONTROL	63
7. REGULATORY SPECIFICATIONS AND METHOD FOR DRUG PRODUCT	65
8. CONTAINER/CLOSURE SYSTEM	77
9. MICROBIOLOGY	80
10. DRUG PRODUCT STABILITY	81
A. Stability Protocol	81
B. Primary Stability Data	82
C. Supportive Stability Data	84
D. Photo Stability Tests	84
E. Stability of Reconstituted Drug Product	85
F. Shipping Stability.....	86
G. Drug Product Shelf Life	87
III. INVESTIGATIONAL FORMULATIONS	88
IV. ENVIRONMENTAL ASSESSMENT	88



CHEMISTRY REVIEW



NDA 21-462 Review #1, ALIMTA™ (pemetrexed disodium) for Injection, Page 4 of 92

V. METHODS VALIDATION 88

VI. LABELING 88

 A. Vial Label and Carton Label 88

 B. Package Insert 90

VII. ESTABLISHMENT INSPECTION 90

VIII. DRAFT DEFICIENCY LETTER 91

**APPEARS THIS WAY
ON ORIGINAL**

Chemistry Review Data Sheet

1. NDA #: 21-462
2. CHEM. REVIEW #: 1
3. REVIEW DATE: Nov. 2, 2003
4. REVIEWER: Chengyi Liang, Ph.D.

5. PREVIOUS DOCUMENTS

Previous Documents

IND 40,061

Document Date

6. SUBMISSION(S) BEING REVIEWED:

Submission(s) Reviewed

Original (DS)

Original (DP)

Amendment

Amendment

Document Date

12-31-2002

09-30-2003

09-30-2003

11-06-2003

7. NAME & ADDRESS OF APPLICANT:

Name:

Eli Lilly and Company

Address:

Lilly Corporate Center

Indianapolis, IN 46285

Representative:

NA

Telephone:

NA

8. DRUG PRODUCT NAME/CODE/TYPE:

a. Proprietary:

Alimta

b. Nonproprietary Name/USAN:

Pemetrexed disodium

c. Code Name/#:

LY231514.2Na.7H₂O

d. Chem. Type/Submission Priority

Chem. Type

1

Submission Priority


P (fast track,
rolling)

9. LEGAL BASIS FOR SUBMISSION:

Fulfilled PDUFA

filing requirements

10. PHARMACOL. CATEGORY/INDICATION: Malignant pleural mesothelioma
11. DOSAGE FORM: for injection (lyophilized powder)
12. STRENGTHS/POTENCY: 500 mg/vial
13. ROUTE OF ADMINISTRATION: IV
14. Rx/OTC DISPENSED: Rx OTC
15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM)
No
16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:



N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt

$C_{20}H_{19}N_5O_6Na_2 \cdot 7H_2O$, MW = 597.49

17. RELATED/SUPPORTING DOCUMENTS:


A. DMFs:

DMF #	TYPE	HOLDER	ITEM REFERENCED	CODE ¹	STATUS ²	DATE REVIEW COMPLETED	COMMENTS
—	III	/		1	adequate	11-20-2003	None
—	III			1	adequate	9-2-2003	None
—	V						9-24-

Chengyi Liang, Ph.D.
Dec., 2003



CHEMISTRY REVIEW



NDA 21-462 Review #1, ALIMTA™ (pemetrexed disodium) for Injection, Page 7 of 92

		/	1	adequate	2001	
--	--	---	---	----------	------	--

1 Action codes for DMF Table:

1 - DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

2 - Type 1 DMF

3 - Reviewed previously and no revision since last review

4 - Sufficient information in application.

5 - Authority to reference not granted

6 - DMF not available

7 - Other (explain under "Comments")

B. Other Documents:

Document	Application Number	Description
IND	40,061	LY231514

18. STATUS:

Consults/CMC Related Reviews	Recommendation	Date	Reviewer
EES	Pending		
OPDRA	Acceptable	7-11-2003	Charlie Hoppes
Methods Validation	Pending		
EA	Categorical exclusion is acceptable	11-20-2003	Chengyi Liang
Microbiology	Acceptable	10-29-2003	Paul Stinavage

The Chemistry Review for NDA 21-462

Chengyi Liang, Ph.D.
Dec., 2003

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

This NDA is recommended to be approved based on the submitted CMC information. The deficiencies related to the drug substance and drug product have been forwarded to the applicant during the fast-track, priority review cycle and resolved as described herein.

B. Recommendation on Phase 4 (post marketing) Commitments, Agreements and/or Risk Management Steps, if Approvable

There are no phase 4 commitments.

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

ALIMTA[®], Pemetrexed for Injection, is a novel antifolate antineoplastic agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication. ALIMTA is supplied as a sterile lyophilized powder for intravenous infusion available in single-dose vials. Each 50 ml vial of ALIMTA contains pemetrexed disodium equivalent to 500 mg pemetrexed free acid and 500 mg of mannitol. Sodium hydroxide and, if necessary, hydrochloric acid are added to adjust pH. The drug product is manufactured by Eli Lilly's facility in France.

The drug substance, containing one chiral center, is / and its structure is well characterized /

The drug substance, drug product, and the reconstituted drug product solution exhibit good stability under various test conditions. The proposed shelf life for the drug productP is 24 months.

B. Description of How The Drug Product Is Intended To Be Used

Pemetrexed is an antifolate containing the structurally novel pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting crucial folate-dependent metabolic processes that are essential for cell replication and then causes mediates cell death by inhibiting DNA synthesis. The applicant proposes /

C. Basis for Approvability Recommendation

The information provided is adequate to support the approval of



CHEMISTRY REVIEW



NDA 21-462 Review #1, ALIMTA™ (pemetrexed disodium) for Injection, Page 9 of 92

this NDA from a CMC perspective.

III. Administrative

A. Reviewer's Signature

/s/

Chengyi Liang, Ph.D.,
Review Chemist

/s/

Richard Lostritto, Ph.D.
Chemistry Team Leader

B. Endorsement Block

Chemist Name/Date: Chengyi Liang, Ph.D.

Chemistry Team Leader Name/Date: Richard Lostritto, Ph.D.

Project Manager Name/Date: Patricia Garvey

C. CC Block

CC:

Orig. NDA 21-462
HFD-150 Division File
HFD-150/CLiang
HFD-150/RLostritto
HFD-150/PGarvey

Chemistry Assessment

INTRODUCTION

Chengyi Liang, Ph.D.
Dec., 2003

Redacted 83

pages of trade

secret and/or

confidential

commercial

information

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Chengyi Liang
12/31/03 02:40:02 PM
CHEMIST

Richard Lostritto
1/5/04 11:29:06 AM
CHEMIST